Mumbai, July 25 -- Drugmaker Cipla Ltd anticipates GLP-1 drugs, used for treating type-2 diabetes and obesity, to be a definite new therapy in the Indian market, and is exploring a wider foray, said chief executive Umang Vohra.

"The Indian market is particularly important to us, where we're looking at the whole GLP-1 category and not just Semaglutide alone," Vohra told reporters in a media interaction on Friday after the company declared its June-quarter results.

Semaglutide, a GLP-1 (glucagon-like peptide-1) drug sold under the brand name Wegovy in India by Novo Nordisk, goes off patent in March 2026.

"Our overall thinking is this is going to be pretty definitive in terms of a new therapy, in terms of a new section of the market and a...